This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Early Movers: Pump Up the Volume

NEW YORK ( TheStreet) -- Several small-cap stocks were poised to move on above-average volume during Thursday's session

Solta Medical (SLTM) jumped by 56 cents, or 25%, to $2.80 in the premarket session after the company said it received approval for a laser device to treat pigmentation. Solta said its Fraxel re:store Dual Laser System can be used both on the face and large body areas to address clearance of pigmentation in a single treatment. The three-month average daily volume for Solta is 89,000, according to Yahoo! Finance.

McClatchy (MNI) tumbled by 53 cents, or 13.2%, to $3.49 in the premarket session after the company reported third-quarter earnings that fell short of the Thomson Reuters average estimate. Revenue dropped 23% from a year ago and also missed expectations. The three-month average daily volume for McClatchy is 2.2 million, according to Yahoo! Finance.

Gray Television (GTN) was rising by 9 cents, or 3.8%, to $2.46 in the premarket session after the company raised its revenue guidance for the third quarter to a range of $66 million to $66.5 million, up from the previous range of $63 million to $64 million, which Gray Television said was due to political issue advertising related to the current national debate on health care reform. Analysts expect third-quarter revenue of $63.6 million, according to Thomson Reuters. The three-month average daily volume for Gray Television is 1.2 million, according to Yahoo! Finance.

BioSante Pharmaceuticals (BPAX) climbed 15 cents, or 8.2%, to $1.97 in the premarket session after Oppenheimer resumed coverage of the company's stock with an outperform rating and a stock price target of $6. The ratings change comes a day after BioSante completed its merger with Cell Genesys. The three-month average daily volume for BioSante is 460,000, according to Yahoo! Finance.

Threshold Pharmaceuticals (THLD) added 17 cents, or 5.1%, to $3.50 in the premarket session after the company announced a licensing agreement granting Eleison Pharmaceuticals exclusive worldwide rights to glufosfamide, which has been evaluated in clinical trials for pancreatic cancer, small cell lung cancer, ovarian cancer and soft tissue sarcoma. The three-month average daily volume for Threshold is 176,000, according to Yahoo! Finance.

Celsion (CLSN) was up 28 cents, or 8%, to $3.79 in the premarket session after the company said it received official approval from China's State Food and Drug Administration for its Clinical Trial Application for ThermoDox. The approval will allow Celsion to include Chinese clinical trial sites in its Phase III ThermoDox HEAT trial for the treatment of primary liver cancer. The three-month average daily volume for Celsion is 61,000, according to Yahoo! Finance.

-- Written by Robert Holmes in New York.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs